Technical Analysis for LXRX - Lexicon Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
D 5.14 0.98% 0.05
LXRX closed up 0.98 percent on Thursday, April 22, 2021, on 58 percent of normal volume.
Earnings due: Apr 26
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Up Down Up
Historical LXRX trend table...

Date Alert Name Type % Chg
MACD Bullish Signal Line Cross Bullish 0.00%
Up 3 Days in a Row Strength 0.00%
Oversold Stochastic Weakness 0.00%
Slingshot Bearish Bearish Swing Setup 0.98%
Oversold Stochastic Weakness 0.98%
Lower Bollinger Band Touch Weakness 5.33%
Oversold Stochastic Weakness 5.33%
Wide Bands Range Expansion 6.20%
Oversold Stochastic Weakness 6.20%
Expansion Breakdown Bearish Swing Setup 1.78%
Older End-of-Day Signals for LXRX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 3% about 8 hours ago
Up 2% about 9 hours ago
60 Minute Opening Range Breakout about 9 hours ago
10 DMA Resistance about 10 hours ago
Down 1% about 10 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Lexicon Pharmaceuticals, Inc. Description

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for human disease. Its portfolio of orally-delivered small molecule compounds in clinical development include LX4211 that has completed two Phase II clinical trials for the treatment of type 1 and type 2 diabetes; LX1032, which is in Phase III clinical trials for the treatment of carcinoid syndrome and ulcerative colitis; and LX1033 that is in Phase II clinical trials for the treatment of irritable bowel syndrome. The company is also developing LX2931 that has completed Phase II clinical trials for the treatment of rheumatoid arthritis; and LX7101, which is in Phase I clinical trials for the treatment of glaucoma. It has drug discovery and development collaborations with Bristol-Myers Squibb Company; Genentech, Inc.; Schering-Plough/Organon; and Takeda Pharmaceutical Company Limited. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Life Sciences Pharmaceutical Industry Clinical Development Diabetes Monoclonal Antibodies Drug Discovery Clinical Trial Rheumatoid Arthritis Ulcer Colitis Glaucoma Takeda Pharmaceutical Company Ulcerative Colitis Human Disease The Woodlands Irritable Bowel Syndrome Treatment Of Glaucoma Biotie Therapies

Is LXRX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 9.65
52 Week Low 1.03
Average Volume 1,054,677
200-Day Moving Average 3.65
50-Day Moving Average 6.47
20-Day Moving Average 5.43
10-Day Moving Average 5.10
Average True Range 0.33
ADX 35.54
+DI 16.53
-DI 28.81
Chandelier Exit (Long, 3 ATRs ) 5.55
Chandelier Exit (Short, 3 ATRs ) 5.69
Upper Bollinger Band 6.15
Lower Bollinger Band 4.70
Percent B (%b) 0.3
BandWidth 26.74
MACD Line -0.40
MACD Signal Line -0.42
MACD Histogram 0.0163
Fundamentals Value
Market Cap 603.82 Million
Num Shares 117 Million
EPS 0.37
Price-to-Earnings (P/E) Ratio 13.93
Price-to-Sales 5.55
Price-to-Book 2.21
PEG Ratio -0.14
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.58
Resistance 3 (R3) 5.58 5.45 5.50
Resistance 2 (R2) 5.45 5.34 5.44 5.48
Resistance 1 (R1) 5.29 5.27 5.37 5.29 5.45
Pivot Point 5.16 5.16 5.20 5.15 5.16
Support 1 (S1) 5.00 5.05 5.08 5.00 4.83
Support 2 (S2) 4.87 4.98 4.86 4.80
Support 3 (S3) 4.71 4.87 4.78
Support 4 (S4) 4.71